

Docket #: S23-099

Massively Parallel Mixed Lymphocyte Reactions

Stanford researchers have developed technology enabling pooling and simultaneous testing of engineered T cells from multiple human donors. This invention increases scale and reduces costs for diagnostic, and pre-clinical development of engineered T cell therapies.

Engineered immune cell testing, particularly CAR-T cells, is costly and time-consuming. A major challenge is the inability to pool T cells from multiple donors due to mutual recognition as foreign cells. In this invention Stanford researchers have developed technology to be able to successfully pool and simultaneously test T cells from multiple human donors without adverse reactions between the T cells from different donors.

Stage of Development

In vitro

Applications

- Cell therapy development
- Cell therapy diagnostic

Advantages

- Scalable
- Significantly cheaper and less resource intensive

Innovators

- Ansuman Satpathy
- Theodore Roth

Licensing Contact

Minxing Li

Licensing and Strategic Alliances Manager

[Email](#)